AQR Capital Management
KRON

AQR Capital Management’s Kronos Bio KRON Stock Holding History

AQR Capital Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,524
Closed -$75K – 2241
2022
Q3 		$75K Sell
22,524
-34,190
-60% -$154K ﹤0.01% 2127
2022
Q2 		$206K Buy
+56,714
New +$257K ﹤0.01% 1988

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

AQR Capital Management's KRON Position: Q4 2022 in Review

AQR Capital Management sold out of Kronos Bio (KRON) in Q4 2022, closing a stake of 22,524 shares — an estimated $75K sold.

AQR Capital Management first reported a position in KRON in Q2 2022 and held it in 2 quarters. The position peaked at $206K in Q2 2022. 97 funds tracked by Wall St. Rank hold KRON as of Q4 2022.

  • AQR Capital Management reported no remaining Kronos Bio position as of Q4 2022 after selling out during the quarter.
  • AQR Capital Management sold 22,524 Kronos Bio shares in Q4 2022, an estimated $75K.
  • AQR Capital Management first reported a position in Kronos Bio in Q2 2022 and held it in 2 quarters.
  • AQR Capital Management's Kronos Bio position peaked at $206K in Q2 2022.
  • 97 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2022.

Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.